As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Ensysce Biosciences, Inc. The largest reported stake is Bob Gene Gower's, at 6.1%. 2 filings are on record since August 12, 2025 (Schedule 13D/A, August 18, 2026).
Sell to companies like Ensysce Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ensysce Biosciences, Inc. has 2 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 6.1% | 1,206,576 | SCHEDULE 13D/A, 2026-08-18 | 2026-08-07 | |
| Adage Capital Management, L.P. | 3.15% | 74,711 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
Holding shares or following this stake? See who's behind Ensysce Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Ensysce Biosciences, Inc. and the records around it.
Ensysce Biosciences, Inc. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Leadership changes Aug 2026
- Form D filing Apr 2025
- Who owns it
Companies that share a holder
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Watch Ensysce Biosciences, Inc.
Get an email when Ensysce Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ensysce Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ensysce Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ensysce Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bob Gene Gower | 1,206,576 | 0 | 1,206,576 | 0 | SCHEDULE 13D/A, 2026-08-18 |
The latest filing identifies Ensysce Biosciences, Inc. by CUSIP 293602504 and gives its principal executive office as 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037 (SCHEDULE 13D/A, 2026-08-18).
Source of funds (Item 3)
On August 7, 2026, personal funds in the amount of $198,000 were used to purchase 400,000 shares of Common Stock at a price per share of $0.495, which purchase triggered the filing of this amended statement on Schedule 13D.Bob Gene Gower, SCHEDULE 13D/A, 2026-08-18
Purpose of Transaction (Item 4)
Bob Gene Gower
The Reporting Person acquired the securities in connection with his service as a director of the Issuer and for investment purposes. In his capacity as the Chairman of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances. Except as set forth herein, the Reporting Person does not have any present plans or proposals at this time that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Support Agreement described in Item 6 of this Schedule 13D will require the Reporting Person to vote in favor of Issuer proposals to be considered at a meeting or meetings of stockholders to: (i) approve the conversion of shares of the Issuer's Series C Non-Voting Convertible Preferred Stock into shares of Common Stock in accordance with the rules of the Nasdaq Stock Market LLC), (ii) if deemed necessary or appropriate by the Issuer or as otherwise required by applicable law or contract, the approval of an amendment to the Issuer's certificate of incorporation, to authorize sufficient shares of Common Stock for the conversion of Series C Preferred Stock issued pursuant to an Agreement and Plan …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-18; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 3.15% | SCHEDULE 13G/A |
| 2026-08-18 | Bob Gene Gower | 6.1% | SCHEDULE 13D/A |
Questions about who owns Ensysce Biosciences, Inc.
Who owns Ensysce Biosciences, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Ensysce Biosciences, Inc.: Bob Gene Gower (6.1%, Schedule 13D/A, filed 2026-08-18).
When did Bob Gene Gower buy into Ensysce Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bob Gene Gower on this page is the Schedule 13D/A, filed 2026-08-18, reporting 6.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Ensysce Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 20, 2026 | Form D, private offering | $77.20M sold | Form D page | Source |
| August 6, 2026 | Leadership change: Lynn Kirkpatrick departs, President, and 1 more | — | Leadership changes | Source |
| April 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| March 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 25, 2025 | Form D, private offering | $2.20M sold | Form D page | Source |
| April 14, 2025 | Form D, private offering | $1.10M sold | Form D page | Source |
Ensysce Biosciences, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Ensysce Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.